Pro-Dex reports Q1 EPS 75c, one estimate 29c
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 31 2024
0mins
Source: Business Insider
Q1 Revenue Performance: The company reported a Q1 revenue of $14.9 million, exceeding estimates of $12.1 million.
Product Shipment Update: CEO Richard L. Van Kirk expressed satisfaction with the results and announced the initial shipment of a new handpiece to their largest customer, with expectations for increased production in the second half of the fiscal year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PDEX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PDEX
About PDEX
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It has an approximately 25,000 square foot industrial building in Tustin, California (the Franklin Property).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pro-Dex Reports Q2 Earnings with Revenue of $1.9M
- Earnings Highlights: Pro-Dex reported a Q2 GAAP EPS of $0.66, with revenue at $1.9 million, indicating stable performance in the niche surgical tools market and reflecting its competitive position in this segment.
- Market Valuation: Pro-Dex is viewed as an attractive microcap despite customer risks, suggesting that its valuation may appeal to investors seeking undervalued opportunities in the market.
- Rating Analysis: Seeking Alpha's quantitative rating on Pro-Dex indicates a cautiously optimistic outlook from the market, highlighting investor interest in its potential growth, particularly in the surgical tools sector.
- Financial Transparency: The disclosure of financial information enhances investor confidence, as stable profitability, despite relatively low revenue, may lay the groundwork for future growth.
Continue Reading
Pro-Dex (PDEX) Extends Major Customer Contract by Three Years, Anticipates Revenue Growth
- Contract Extension: Pro-Dex executed a contract amendment on December 17, 2025, with its largest customer, extending the agreement through December 31, 2028, which includes minimum purchase volumes, thereby positioning the company for sustained revenue growth over the next three years.
- Sales Performance Surge: For the fiscal first quarter ending September 30, 2025, Pro-Dex reported net sales of $18.5 million, a 24% increase from $14.9 million year-over-year, primarily driven by resumed shipments to its largest customer, indicating robust market demand.
- Net Income Growth: The company's net income rose to $4.7 million, or $1.40 per diluted share, compared to $2.5 million, or $0.75 per diluted share a year earlier, reflecting the successful launch and sales of its next-generation surgical handpiece.
- Optimistic Market Outlook: Pro-Dex anticipates that the extended contract will provide stability as it continues to innovate in surgical instrumentation and expand consulting services, further solidifying its position in the medical device market.
Continue Reading